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Background: Neuroblastoma (NBL) accounts for 8% to 10% of all 
childhood cancers, and more than half of these cases are advanced 
stages. Vigorous research on single, tandem or triple high-dose 
chemotherapy (HDCT) and autologous stem cell rescue therapy have 
improved the survival of many high-risk NBL patients, however, 
patients remain to have a dismal prognosis.  
In 2002, the Korean National Health Insurance policy extended 
coverage to include children over 1 year of age diagnosed with stage 
IV that showed partial response to surgery or chemotherapy and stage 
III in which complete resection was infeasible. As the burden of 
medical expenses was lifted, high-risk NBL patients were able to 
receive tandem HDCT more readily. The objective of this study was to 
conduct a historical analysis of patient outcome after the 
implementation of the Korean health care reform.  
Methods: During the period between October 1997 and December 
2010, a retrospective analysis was performed of 60 patients with stage 
III or IV NBL who received single or tandem HDCT with stem cell 
rescue therapy at Seoul National University Children’s Hospital 
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(SNUCH). The overall survival (OS) and event-free survival (EFS) 
were analyzed. 
Results: Sixty patients diagnosed with NBL received single or tandem 
HDCT and autologous stem cell rescue therapy. Five-year OS of the 
single and tandem group were 82.9% (95% CI, 69.4%-96.4%) and 
85.6% (95% CI, 72.5%-98.7%), respectively (P=0.590). Five-year EFS 
of the single and tandem group were 52.9% (95% CI, 30.9%-67.4%) 
and 71.4% (95% CI, 43.3%-81.0%) (P=0.234). An event was more 
likely attributed to relapse, rather than treatment related mortality 
(TRM).  
Conclusion: With the change of the Korean National Health Insurance 
policy, an improvement of outcome in NBL patients receiving 
autologous stem cell rescue was observed. However, relapse remains 
to be an issue. As subclinical disease activity is correlated with disease 
relapse, monitoring disease activity before relapse is crucial and 
identifying molecular targets for future therapies are warranted. 
---------------------------------------------------------------------------------------------- 
Key words: neuroblastoma, high-risk, tandem, high-dose 
chemotherapy, autologous peripheral blood stem cell transplantation  
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   Neuroblastoma (NBL) is a neuroendocrine tumor, derived from 
neural crest tissues of the sympathetic nervous system. It accounts for 
8% to 10% of all childhood cancers and is the most common 
extracranial solid tumor in childhood (1,2). As one of the most 
enigmatic disease entities exhibiting striking heterogeneity, it has been 
known to spontaneously regress when developed in those less than 
one year of age. Unfortunately, more than half of patients are 
advanced stages when diagnosed and continue to exhibit a dismal 
prognosis. 
In 2002, the Korean National Health Insurance policy extended 
coverage to children over 1 year of age diagnosed with stage IV that 
showed partial response to surgery or chemotherapy and stage III in 
which complete resection was infeasible. Prior to March of 2002, NBL 
patients received myeloablative chemotherapy followed by a single 
course of autologous peripheral blood stem cell transplantation 
(PBSCT). However, after reforms in the Korean Health Care policy, 
patients were able to receive tandem HDCT with rapid bone marrow 
reconstitution as the burden of treatment expenses was lifted. This 
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change was in large part due to evidence of randomized pilot studies 
that showed that myeloablative consolidation combined with stem cell 
rescue therapy improved the dismal outcome of high-risk patients 
(3,4,5). However, treatment failure after high-dose chemotherapy 
(HDCT) followed by stem cell rescue therapy remains to be 
problematic with relapse, rather than treatment-related mortality (TRM), 
being the main cause (6).  
Therefore, the objective of this study was to conduct a historical 
analysis of patient outcome after the implementation of the Korean 
health care reform. Patient characteristics and outcome of stage 3 or 4 
NBL patients who received PBSCT at Seoul National University 
Children’s Hospital (SNUCH) were reviewed. In addition, the causes of 










Patients and Methods 
 
Patients 
From October 1997 to December 2010, a retrospective analysis 
was performed of hospitalization records of 60 newly diagnosed NBL 
patients that received PBSCT at SNUCH of Seoul, Korea. With the 
change of National Health Care coverage in 2002, patients receiving 
autologous stem cell transplantation prior to March 2002 received 
single HDCT, whereas after March 2002, patients were able to receive 
tandem HDCT as the burden of medical expenses was lifted. The 
patients that received single HDCT are referred to as the single group, 
and those that received tandem HDCT are referred to as the tandem 
group. Patient sex, age, disease status, conditioning regimen received, 





Induction and Consolidation 
After diagnosis, patients received induction therapy that consisted 
of a minimum of 4-5 cycles of CCG-321-P2 (cisplatin, adriamycin, 
cyclophosphamide, vincristine) chemotherapy regimen (Table 1) (7). 
Patients were re-evaluated after induction and received surgical 
resection, if deemed a surgical candidate. After the completion of 
induction therapy, peripheral blood stem cell mobilization (PBSCM) 
was performed. These stem cells were cryopreserved and later infused 
back to the patient after the patient received myeloablative 
chemotherapy as autologous hematopoietic stem cell rescue therapy.  
HDCT was defined as chemotherapy that induced bone marrow 
cell depletion to the state of necessitating stem cell rescue therapy. 
Patients that received single HDCT received either MEC (Melphalan, 
Etoposide, Carboplatin) or TMC (Topotecan, Melphalan, Carboplatin) 
regimen (8,9). Patients that received tandem HDCT received TTC 
(Topotecan, Thiotepa, Carboplatin), followed by MEC or mMEC 
(modified MEC) (Table 1). 
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In June of 2007, a modification of carboplatin dose was implemented 
to those receiving tandem HDCT, as patients were observed to 
experience renal toxicity. Patients that received 400mg/m2 of 
carboplatin are referred to as the MEC group, and those that received 
350mg/m2 of carboplatin are referred to as the modified MEC (mMEC) 
group. 
Post-HDCT or autologous SCT treatment consisted of 13-cis-retinoic 
acid (isotretinoin; ITT), IL-2, and radiotherapy. IL-2 was started when 
an increase of ANC greater than 1.0x109/L and platelet count of 
greater than 50x109/L without transfusion was observed after the 
completion of tandem HDCT. Local radiotherapy was initiated after day 








Stem Cell Mobilization and CD 34+ Selection 
Prior to receiving HDCT, all patients underwent the process of stem 
cell mobilization. After receiving peripheral blood stem cell mobilization 
(PBSCM) chemotherapy (Table 2), patients received subcutaneous 
injections of high dose G-CSF (10 μg/kg) starting from day 7 and until 
a white blood cell (WBC) count of 1.0x109/L was achieved.  
Patients received leukapheresis and CD34+ cell selection was 
performed to decrease the potential of tumor contamination, after 
which the cells were cryopreserved. CD34+ cell selection was 
performed using CliniMACS® CD34 Reagent System (Miltenyi Biotec, 
Bergisch Gladbach, Germany). 
 
Supportive Care 
As infection prophylaxis and supportive care plays a pivotal role in 
patient survival after SCT, we employed the following conservative 
management processes. Patients received low-molecular weight 
(LMW) heparin (Nadroparine) or lipo-PGE1 (Eglandin) from the start of 
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HDCT as prophylaxis against veno-occlusive disease (VOD). Patients 
received granulocyte colony-stimulating factor (G-CSF) 300μg/m2/d 
subcutaneously, starting on d1, and was discontinued when absolute 
neutrophil count (ANC) increased to more than 1.0x109/L for three 
consecutive days. If the patient spiked a fever of 38.0℃, broad 
spectrum antibiotics were administered. Patients received acyclovir, 
ciprofloxacin, micafungin, and isoniazid for prophylaxis against 
opportunistic infections.  
 
Statistical Analysis 
All data were analyzed using the standard statistical methods using the 
Statistical Package for the Social Sciences for Windows software 
(SPSS) version 19.0 program. Event-free survival (EFS) was defined 
as the time from diagnosis to the first event. An event was defined as 
occurrence of progression, relapse, or death. Overall survival (OS) 
was defined as the time from diagnosis to the time of death or time of 
last contact if the patient did not die. Survival data with 95% 
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confidence interval (CI) was obtained by performing Kaplan-Meier 
statistical analysis and log-rank test. Characteristics of the two groups 
were compared using Chi-square test or Fisher’s exact test. Also, Cox-
regression analysis was performed to evaluate the prognostic factors 
of variables at the time of diagnosis for EFS. P-value < 0.05 was 














Table 1. Schema of induction and consolidation chemotherapy 
Induction chemotherapy 
Cisplatin 60mg/m2 (day 1) 
Etoposide 100 mg/m2 (day 2) 
Doxorubicin 30mg/m2 (day 2) 
Cyclophosphamide 30mg/kg (day 3,4) 
 
Table 2. Schema of peripheral blood stem cell mobilization 
PBSCM chemotherapy 
Cyclophosphamide 1,000mg/m2 (day 0 ~ day 2) 
MESNA 1,500 mg/m2 (day 0~ day 2) 
Etoposide 150mg/m2 (day 0 ~ day 2) 
G-CSF 10 μg/kg (day 7~) 










Table 3. Schema of high-dose chemotherapy prior to autologous stem 
cell rescue therapy 
Single HDCT 
MEC  Melphalan 140mg/m2 or 70mg/m2 (day -7,-6) 
      Etoposide 200mg/m2 (day -8 ~ -5) 
      Carboplatin 400mg/m2 (day -8 ~ -5) 
Or 
TMC  Topotecan 20mg/m2 (day -8~-4) 
      Melphalan 140mg/m2 or 70mg/m2 (day -7 ~ -6) 
      Carboplatin 500mg/m2 (day -5 ~ -3) 
Tandem HDCT 
TTC  Topotecan 2mg/m2 (day -8 ~ -4) 
      Thiotepa 300mg/m2 (day -8 ~ -6) 
      Carboplatin 500mg/m2 (day -5 ~ -3) 
and 
MEC  Melphalan 140mg/m2 or 70mg/m2 (day -7,-6) 
      Etoposide 200mg/m2 (day -8 ~ -5) 




mMEC  Melphalan 140mg/m2 or 70mg/m2 (day -7,-6) 
        Etoposide 200mg/m2 (day -8 ~ -5) 
        Carboplatin 350mg/m2 (day -8 ~ -5) 


















Characteristics of patients 
As a retrospective analysis, this study observed the outcome of high-
risk NBL patients treated with HDCT and autologous stem cell rescue 
therapy. Patient outcomes were investigated by both intention-to-treat 
and per-protocol analysis (10).  
From October 1997 to December 2010, 60 newly diagnosed high-risk 
NBL patients received HDCT and stem cell rescue therapy at SNUCH 
of Seoul, Korea. Of the 60 patients newly diagnosed with high-risk 
NBL, 24 patients were designated to receive single HDCT, referred to 
as the single group and 36 patients were designated to receive tandem 
HDCT, referred to as the tandem group. Within the single group, one 
patient died from treatment-related cause of veno-occlusive disease 
(VOD), 11 patients relapsed, two patients could not be followed up, 
and 10 patients remain to be relapse-free. Of the 11 patients that 
relapsed, eight patients were lost in follow up, one patient died from 
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candidal infection, one patient is alive and receiving palliative 
chemotherapy, and one patient is alive and disease-free. 
Out of the total of 36 patients who were designated to receive tandem 
HDCT, eight patients received single HDCT and 28 patients received 
tandem HDCT. Of the patients that received single HDCT, one patient 
died of acute renal failure (ARF) cause, three patients progressed, one 
patient relapsed, and three patients remain relapse-free. Of the 28 
patients that received tandem HDCT, two patients died of TRM 
(specifically, ARF and septic shock), seven patients relapsed, and 19 
patients remain relapse-free.  
Therefore, 32 patients ultimately received single HDCT, and 28 
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The median duration of follow up was 69.5 months (range, 10 - 198 
months) for the single group and 64.6 months (range 9 – 137 months) 
for the tandem group. Patients ≥ 18 months of age consisted 78.1% 
(n=25) of the single group and 82.1% of the tandem group (n=23) 
(P=0.698). The primary site was most commonly located in the 
abdomen and MYCN amplification was present in 12.5% (n=4) of the 
single group and 60.7% (n=17) of the tandem group (P <0.001). 
Patients showed bone marrow metastasis at diagnosis in 78.1% 
(n=25) of the single group and 53.6% (n=15) of the tandem group. 
Bone metastasis at diagnosis was discovered in 84.4% (n=27) of the 
single group and 50.0% (n=14) of the tandem group. In order to reduce 
tumor cell contamination of PBSCs, positive selection of CD34+ cells 
was performed in 62.0% (n=20) of cases in the single group and 
92.9% (n=26) of the tandem group. The demographic data are 




Table 4. Demographic data of patients. 
Parameters Single group 
(n=32) 
Tandem group 
    (n=28) 
P value 
Sex 
   Female 
   Male 
Age at diagnosis 
   < 18 months 
   ≥ 18 months 
 
Primary site 





   Amplified 
   Not amplified 








   No 
   Yes 
CD 34+ selection 
   No 























































































Patient outcome was analyzed per-protocol received. The 5-year OS 
and EFS of the single and tandem group were analyzed. Five-year OS 
of the single and tandem group were 82.9% (95% CI, 69.4%-96.4%) 
and 85.6% (95% CI, 72.5%-98.7%), respectively (P=0.590). Five-year 
EFS of the single and tandem group were 52.9% (95% CI, 30.9%-
67.4%) and 71.4% (95% CI, 43.3%-81.0%) (P=0.234) (Figure 2). 
Multivariate analyses of the prognostic factors at diagnosis for EFS 
revealed bone metastasis at diagnosis to be significantly correlated 
with an unfavorable outcome (hazard ratio 2.82, 95% CI 1.06-7.05, 













Figure 2. Kaplain-Meier analysis of patient outcome. Five-year 
overall survival (OS) and event-free survival (EFS) of the single and 
tandem group are depicted. (A) The OS of the single group was 82.9% 
(n=32) and 85.6% (n=28) in the tandem group (P=0.590). (B) Five-year 





Table 5. Multivariate analysis of variables at diagnosis of EFS. 
 Univariate analysis  Multivariate analysis 
Variables HR 95% 
CI 





















































1.03 0.968  1.44 0.381 
Age at  
≥ 18mon.  
 




































































The major cause of events in patients was observed to be relapse, 
as opposed to TRM. Twelve of 32 patients relapsed in the single group 
and TRM attributed to VOD and ARF was noted. Seven of 28 patients 
relapsed in the tandem group and 2 cases of TRM related to ARF were 
noted.  
As patients were observed to experience renal toxicity, a decrease in 
carboplatin dosage from 400mg/m2 to 350mg/m2 was implemented in 
the second myeloablative conditioning regimen in June of 2007. Of the 
patients that received tandem HDCT, patients that received 400mg/m2 
of carboplatin are referred to as the MEC group and those that 
received a modified dose 350mg/m2 of carboplatin are referred to as 
the mMEC group. Five-year OS and EFS of the two groups were 
compared and are depicted in figure 3. In comparing the MEC and 
mMEC group, EFS was defined as the time from PBSCT to the first 
event and OS was defined as the time from PBSCT to the time of 
death or last time of follow up if the patient did not die. The 5-year OS 
in the MEC and mMEC group were 81.8% (n=11) and 88.2% (n=17), 
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respectively (P=0.611). The 5-year EFS of the MEC and mMEC group 






















Figure 3. Of the patients that received tandem HDCT, survival of 
patients that received different doses of carboplatin during 
myeloablative conditioning. The MEC group received 400mg/m2 of 
carboplatin and mMEC group received 350mg/m2 of carboplatin. (A) Five-
year OS of the MEC and mMEC group were 81.8% (n=11) and 88.2% 
(n=17), respectively (P=0.611). (B) Five-year EFS of the MEC and mMEC 




As tandem HDCT has shown to improve the survival of patients 
with high-risk NBL, it was included in the National Health Insurance 
coverage in the year 2002. The objective of this study was to 
investigate the clinical characteristics and outcome of patients that 
received single and tandem HDCT combined with autologous stem cell 
rescue therapy as a result of health care reform. Also, investigation 
into the events that caused treatment failure was initiated.  
In 2010, the Korean Society of Pediatric Hematology-Oncology 
reported of the 5-year EFS of patients that received tandem HDCT and 
stem cell rescue therapy. The results showed higher survival in 
patients that received tandem HDCT with 5-year EFS of 51.2 ±12.4% 
(P=0.030) (11). In the present study, the 5-year OS and EFS of the 
single and tandem groups were obtained. The outcome of patients that 
received tandem HDCT suggests that an improvement of OS and EFS 
in patients with high-risk NBL is plausible. The Children’s Oncology 
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Group (COG) has previously reported of a cooperative group setting 
for tandem autologous PBSCT with overall 5-year progression-free 
survival (PFS) and OS of 24.2% ± 7.5% and 36.4% ± 8.4% (n=33) 
(12).  
The main cause of an event in patients appeared to be relapse. 
Although the results of 5-year OS and EFS appeared promising, 
investigation into the 10-year OS and EFS of the two groups revealed 
that relapse was observed after 5 years of receiving stem cell rescue 
therapy in the single group. The 10-year OS of the single and tandem 
groups were 77.1% (95% CI, 60.2%-93.9%) and 85.6% (95% CI, 
72.4%-98.7%) (P=0.590). This suggests that a long-term follow up 
period is needed. Other studies have also supported this finding that 
relapse or tumor progression rather than TRM is the cause of 
treatment failure (13). In one study reported by George et al., the 
majority of relapses occurred at metastatic sites, most commonly at 
the bone, bone marrow, and liver (14). 
In the present study, a greater incidence of relapse was observed 
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in the single group, and 4 of the 8 patients that were intended to 
receive tandem HDCT but received single HDCT for other causes was 
due to disease progression or relapse. This leads to the thought that a 
shorter interval between the first and second HDCT may decrease 
relapse rates and warrants further investigation. A study of rapid 
sequence tandem HDCT was explored by Grupp et al. and yielded a 3-
year EFS of 63% (15). In one report, Philips et al. (16) reported of 
using tandem HDCT with bone marrow as the source of stem cells. 
The regimen required a significant time interval between stem cell 
rescue and TRM was reported from delayed engraftment (17). 
Therefore, an optimal interval between PBSCTs has yet to be defined. 
As targeting subclinical disease activity is correlated with disease 
relapse, efforts of monitoring disease activity before relapse have been 
actively pursued. Accurate monitoring of minimal residual disease 
(MRD) with molecular markers could sophisticate the optimal timing of 
surgery and tandem HDCT for a specific patient. Polymerase chain 
reaction (PCR) detection of MRD has been used to monitor therapy 
response with markers, such as tyrosine hydroxylase (TH) and 
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disialoganglioside (GD)2 synthase, however their uses are limited in 
that they are also expressed in normal peripheral nerves and the 
cerebellum (17). Nonetheless, successful treatment with anti-GD2 
monoclonal antibody to prevent relapse has been reported (18). 
Methods of measuring MRD with novel markers have been proposed 
and include cyclin D1 (CCND1), a cell-cycle control gene (19), gamma-
aminobutyric acid (GABA) A receptor, beta 3 (GABRB3), ISL LIM 
homeobox1 (ISL1), kinesin family member 1A (KIF1A) and PHOX2B 
(17) (paired-like homeobox 2b). These molecular markers were found 
to be significantly accurate in testing the progress-free survival (PFS) 
of NBL patients (20). 
In the present study, TRM was observed to be attributed to renal 
toxicity and a lower incidence was observed in patients who received 
lower doses of carboplatin. Therefore, it was hypothesized that a 
conditioning regimen related to renal toxicity may play a factor in 
increasing TRM. After making adjustment to the dose of carboplatin, 
patient outcome suggests that an improvement in OS and EFS could 
be achieved (P=0.611, P=0.400). Although the EFS and OS were not 
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statistically significant between the single and tandem group, improved 
OS and EFS in high-risk NBL patients was suggested, which may also 
be due to the improved salvage therapy and supportive care. In other 
words, it is important to note that an improved outcome after 
myeloablative chemotherapy followed by stem cell rescue therapy 
should be viewed in context of the complete therapy, with 
consideration of the salvage therapy and previous therapy of induction 
chemotherapy, surgery, and/or radiotherapy (1).  
The issue of CD34+ selection in autologous SCT has been  
controversial, as definitive evidence of its benefits have been unclear. 
Recent evidence suggests that CD34 expression does not necessarily 
correlate with stem cell activity (21). In concept, the process of 
positively selecting CD34 cells and purging PBSCs is performed to 
reduce tumor contamination and has been shown to improve outcome 
for patients with high-risk NBL (22). However, a randomized phase 3 
trial conducted by the COG (COG A3973) has established that ex vivo 
purging of PBSCs for autologous PBSCT did not improve outcome of 
high-risk NBL patients (1). In the present study, definitive evidence of 
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the benefits of CD34+ selection could not be delineated and warrants 
further investigation with a larger pool. 
Limitations of this study include the retrospective nature of the 
analysis and a lack of a long-term follow up period. Also, because 
patients were not allocated single or tandem HDCT during the same 
time period, it is difficult to conclude that the improvement of patient 
outcome is solely due to the effects of tandem HDCT. As the 
improvement of other salvage therapies that accompanied the 
passage of time may confound benefits of tandem HDCT.  
Also, it should be noted that eight of the 11 patients that relapsed in 
the single group were lost in follow up. Their data were censored off 
during analysis, and censoring also affects survival rates. Because 
censoring removes subjects from the dominator, such as individuals 
still at risk, a large number of patients lost in follow up influences the 
survival rates of the group (23).     
In conclusion, the outcome of high-risk NBL patients has improved with 
the implementation of the Korean National Health Insurance policy 
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reform. As relapse is the main cause of treatment failure for NBL 
patients receiving PBSCT, future trials should be directed on 
monitoring disease activity from the molecular level and evaluating the 
effectiveness of a shorter time interval between PBSCTs. As patient 
outcome differs from each institution, future trials with carefully 
designed regimens that investigate the optimal induction and 














1.  Bilgehan Y, Leontien CM K, Huib N C, Elvira C. High-dose 
chemotherapy and autologous haematopoietic stem cell rescue for 
children with high-risk neuroblastoma. Cochrane Database Syst Rev. 
2013 Aug 22;8. 
 
2. Aydin GB, Kutluk MT, Yalçin B, Büyükpamukçu M, Kale G, Varan A, 
et al.Neuroblastoma in Turkish children: experience of a single center. 
Journal of Pediatric Hematology and Oncology 2009;31:471–80. 
 
3. Mathay KK, Villabland JG, Seeger RC, Stram DO, et al. Treatment 
of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, 
autologous bone marrow transplantation, and 13-cis-retinoic acid. 
Children’s Cancer Group. N Eng J Med 1999;341:1165-73. 
 
4. Berthold F, Boos J, Burdach S, Erttmann R, et al. Myeloablative 
megatherapy with autologous stem-cell rescue versus oral 
maintenance chemotherapy as consolidation treatment in patients with 
31 
 
high-risk neuroblastoma: a randomized controlled trial. Lancet Oncol 
2005;6:649-58. 
 
5. Qayed M, Chiang KY, Ricketts R, Alazraki A, et al. Tandem Stem 
Cell Rescue as Consolidation Therapy for High-Risk Neuroblastoma. 
Pediatr Blood Cancer 2012; 58:448-452. 
 
6. Sung KW, Son MH, Lee SH, Yoo KH, Koo HH, Kim JY, et al. 
Tandem high-dose chemotherapy and autologous stem cell 
transplantation in patients with high-risk neuroblastoma: results of 
SMC NB-2004 study. Bone Marrow Transplant. 2013 Jan;48(1):68-73. 
 
7. O’leary MC, Sather HN, Ramsay NK, Harris R, et al. Intensive 
chemotherapy for poor prognosis neuroblastoma. Proc Am Assoc 
Cancer Res 1990;31:201. 
 
8. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 
years in the LMCE1 unselected group of 72 children with stage IV 
neuroblastoma older than 1 year of age at diagnosis: is cure possible 
in a small subgroup? J Clin Oncol 9:1037-1044, 1991. 
32 
 
9. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, et al. Topotecan 
combined with myeloablative doses of thiotepa and carboplatin for 
neuroblastoma, brain tumor, and other poor-risk solid tumors in 
children and young adults. Bone Marrow Transplant. 2001 28(6):551-6. 
 
10. Lachin JM. Statistical considerations in the intent-to-treat principle. 
Controlled Clinical Trials 2000;21:167–89. 
 
11. Sung KW, Ahn HS, Cho B, Choi YM, et al. Efficacy of Tandem 
High-Dose Chemotherapy and Autologous Stem Cell Rescue in 
Patients Over 1 Year of Age with Stage 4 Neuroblastoma: The Korean 
Society of Pediatric Hematology-Oncology Experience Over 6 Years 
(2000-2005). J Korean Med Sci 2010;25:691-7. 
 
12. Granger M, Grupp SA, Kletzel M, et al. Feasibility of Tandem 
Autologous Peripheral Blood Stem Cell Transplant Regimen for High 
Risk Neuroblastoma in a Cooperative Group Setting: A Pediatric 
Oncology Group Study: A Report from the Children’s Oncology Group. 




13. Kim EK, Kang HJ, Park JA, Choi HS, et al. Retrospective Analysis 
of Peripheral Blood Stem Cell Transplantation for the Treatment of 
High-Risk Neuroblastoma. J Korean Med Sci. 2007:22(suppl):S66-72. 
 
14. George RE, Li S, Medeiros-Nancarrow C. High-risk neuroblastoma  
treated with tandem autologous peripheral-blood stem cell-supported 
transplantation: long-term survival update. J Clin Oncol. 2006 Jun 
20;24(18):2891-6. 
 
15. Grupp SA, Stern JW, Bunin N, Allmen DV, et al. Rapid Sequence 
Tandem Transplant in Children with High-Risk Neuroblastoma. 
Transplantation in Hematology and Oncology II. 2003, pp270-279. 
 
16. Philip T, Ladenstein R, Zucker JM, et al: Double megatherapy and 
autologous bone marrow transplantation for advanced neuroblastoma: 
The LMCE2 study. Br J Cancer 67:119-127, 1993. 
 
17. Stutterheim J, Gerritsen A, Kleijn I, Dee R, et al. PHOX2B Is a 
Novel and Specific Marker for Minimal Residual Disease Testing in 
Neuroblastoma. Journal of Clinical Oncology (2008) 26:5443-5449. 
34 
 
18. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld 
RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-
mediated lysis of human neuroblastoma cells. Cancer Res. 
1991;51:144-9. 
 
19. Cheung IY, Fend Y, Vickers A, Gerald W, et al. Cyclin D1,a Novel 
Molecular Marker of Minimal Residual Disease, in Metastatic 
Neuroblastoma. J Mol Diagn. 2007 April;9(2):237-241. 
 
20. Kagedal Bertil. Detecting MRD in Neuroblastoma: Still a Ways to 
Go. Clinical Chemistry (2009) 55:7. 
 
21. Dao MA, Nolta JA. CD34: to select or not to select? That is the 
question. Leukemia. 2000 May;14(5):773-6. 
 
22. Kreissman SG, Villablanca JG, Seeger RC, et al. Purged versus 
non-purged peripheral blood stem-cell transplantation for high-risk 
neuroblastoma (COG A3973): a randomized phase 3 trial. Lancet 




23. Rich JT, Neely, JG, Paniello RC, et al. A practical guide to 
understanding Kaplan-Meier curves. Otolaryngology-Head and Neck 
Surgery (2010) 143:331-336. 
 
